• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
98% Bifida Ferment Lysate
rhSOD (cosmetic grade)
Recombinant humanized collagen
Recombinant Humanized Small-molecule Collagen
Recombinant Humanized Small-molecule Collagen Solution
rhSOD

Claris completes sale of its stake in JV to Otsuka

expressbpdSeptember 26, 2017

Tag: Claris , JV , Otsuka

The agreement to sell was announced on May 8, 2017

Claris Lifesciences has recently completed the sale of its remaining 20 per cent stake in Otsuka Pharmaceutical India; the joint venture with Otsuka Pharmaceutical Factory, and Mitsui & Co.; to Otsuka Pharmaceutical Factory, for a consideration of $ 20 million.

In the July, 2017 the company has also completed the sale of its global generic injectables business to Baxter international for an enterprise value of $ 625 million.

Previous:Bayer backs new mobile eye unit in Hampshire

Next:BioAscent Discovery in agreement with Pivot Park Screening Centre

Related News

Prenetics' IM8 Announces Collaboration with Mayo Clinic to Develop New Line of Premium Supplements

PRNewswireDecember 19, 2024

A New Premium Supplements Brand, Launched Officially on November 18th on IM8health.com

PeproMene Bio, Inc. and the Institute for Follicular Lymphoma Innovation Announce $11M Investment to Advance PMB-CT01 (BAFF-R CAR T cell therapy) for Relapsed/Refractory Follicular Lymphoma

PRNewswireDecember 19, 2024

Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration

PRNewswireDecember 20, 2024

Claris completes sale of its stake in JV to Otsuka | Pharmasources.com

Corvia Medical Achieves CE Certification for Atrial Shunt Under New EU MDR Standards

PRNewswireDecember 21, 2024

Corvia Medical, Inc.announced today that it has achieved CE certification for the Corvia® Atrial Shunt System under the latest EU Medical Device Regulations (EU MDR 2017/745).

You may like
More>>

PHENOXYMETHYL PENICILLIN POTASSIUM

PHENOXYMETHYL PENICILLIN POTASSIUM
LINCOMYCIN HCL

LINCOMYCIN HCL
GENTAMYCIN SULPHATE macrolides

GENTAMYCIN SULPHATE macrolides
CEFALEXINE cephalosporins

CEFALEXINE cephalosporins
CEFRADINE cephalosporins

CEFRADINE cephalosporins
CEFADROXIL cephalosporins

CEFADROXIL cephalosporins
CEFIXIME cephalosporins

CEFIXIME cephalosporins
CEFATHIAMIDINE cephalosporins

CEFATHIAMIDINE cephalosporins
CEFMINOX SODIUM cephalosporins

CEFMINOX SODIUM cephalosporins
CEFOXITIN SODIUM cephalosporins

CEFOXITIN SODIUM cephalosporins

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service